Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Gene-edited pig cardiac xenotransplantation as a bridge to allotransplantation in infants: Progress in a pig-to-baboon model

Key Takeaway: The article discusses advancements in gene-edited pig cardiac xenotransplantation, particularly its potential as a bridge to allotransplantation in infants. It highlights progress made in a pig-to-baboon model, showcasing the innovative approach and its implications for future transplant procedures. This research could significantly impact organ transplantation strategies.
Price reaction · baseline $1.575 (2025-12-24T17:34:00.000Z) · hit during market hours · 1 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Progress in gene-edited pig cardiac xenotransplantation.
  • Potential to bridge to allotransplantation in infants.
  • Innovative approach using a pig-to-baboon model.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is gene-edited pig cardiac xenotransplantation?

It is a technique using genetically modified pigs to provide hearts for transplantation.

How does this research impact infants needing transplants?

It offers a potential bridge to allotransplantation, improving options for infant patients.

What model was used in this study?

The study utilized a pig-to-baboon model to test the xenotransplantation approach.

What are the implications of this research?

This research could enhance organ transplantation strategies and patient outcomes.

Last updated: Dec 24, 2025